References
- Bronner L. L., Kanter D. S., Manson J. E. Primary prevention of stroke. N Engl J Med 1995; 333: 1392–1400
- Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., , VALUE trial group, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022–2031
- Dahlof B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., , LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention FOR Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003
- Ito T., Yamakawa H., Bregonzio C., Terron J. A., Falcon‐Neri A., Saavedra J. M. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an AT1 antagonist. Stroke 2002; 33: 2297–2303
- Ludwig M., Stapff M., Ribeiro A., Fritschka E., Tholl U., Smith R. D., et al. Comparison of the effect of losartan and atenolol on common carotid artery intima‐media thickness in patients with hypertension. Clin Ther 2002; 24: 1175–1193
- Uchiyama‐Tanaka Y., Mori Y., Kishimoto N., Fukui M., Nose A., Kijima Y., et al. Comparison of the effects of quinapril and losartan on carotid artery intima‐media thickness in patients with mild‐to‐moderate arterial hypertension. Kidney Blood Press Res 2005; 28: 111–116
- Hilton E. J., Hosking Sl., Betts T. Epilepsy patients treated with antiepileptic drug exhibit compromised ocular perfusion characteristics. Epilepsia 2002; 43: 1346–1350
- Delles C., Michelson G., Harazny J., Oehmer S., Hilgers K. F., Schmieder R. E. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004; 35: 1289–1293
- Michelson G., Welzenbach J., Pal I., Harazny J. Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol 1998; 82: 1294–1300
- Michelson G., Patzelt A., Harazny J. Flickering light increases retinal blood flow. Retina 2002; 22: 336–343
- Kondo M., Wang L., Bill A. The role of nitric oxide in hyperaemic response to flicker in the retina and optic nerve in cats. Acta Ophthalmol Scand 1997; 75: 232–235
- Donati G., Pournaras C. J., Munoz J. L., Poitry S., Poitry‐Yamate C. L., Tsacopoulos M. Nitric oxide controls arteriolar tone in the retina of the miniature pig. Invest Ophthalmol Vis Sci 1995; 36: 2228–2237
- Buerk D. G., Riva C. E., Cranstoun S. D. Nitric oxide has a vasodilatory role in cat optic nerve head during flicker stimuli. Microvasc Res 1996; 52: 13–26
- Dorner G. T., Garhofer G., Kiss B., Polska E., Polak K., Riva C. E., et al. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol 2003; 285: H631–H636
- Mayer B. X., Mensik C., Krishnaswami S., Derendorf H., Eichler H. G., Schmetterer L., et al. Pharmacokinetic–pharmacodynamic profile of systemic nitric oxide‐synthase inhibition with L‐NMMA in humans. Br J Clin Pharmacol 1999; 47: 539–544
- Delles C., Jacobi J., Schlaich M. P., John S., Schmieder R. E. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 2002; 15: 3–9
- Delles C., Jacobi J., John S., Fleischmann I., Schmieder R. E. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002; 61: 1462–1468
- Ghiadoni L., Virdis A., Magagna A., Taddei S., Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 501–506
- Prasad A., Halcox J. P., Waclawiw M. A., Quyyumi A. A. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol 2001; 38: 1089–1095